27.05.2014 - Pfizer declined from purchasing AstraZeneca

Pharmaceutical giant Pfizer on Monday officially refused to buy AstraZeneca for $ 120 billion. The reason for failure of the transaction was the disagreement between the shareholders of AstraZeneca and the corporation Pfizer, which offered 55 pounds per share against the request of shareholders of 58.85 pounds. Moreover, part of AstraZeneca shareholders believe that the company can improve its performance through investing in its own production of drugs against cancer, respiratory diseases and diabetes.

Currently pharmaceutical sector looks attractive for long term investment. On this background we maintain our positive outlook on the stock, due to the stable development of the company and growth financial indicators.

Pfizer Icon

RISK WARNING: Trading of complex financial products, such as Stocks, Futures, Foreign Exchange ("Forex"), Contracts for Difference ("CFDs"), Indices, Options, or other financial derivatives, on "margin" carries a high level of risk, and may not be suitable for all investors. The possibility exists that you could sustain a loss of some or all of your initial investment and, therefore, you should not invest money that you cannot afford to lose. You should be aware of all the risks associated with trading these markets, and seek advice from an independent financial advisor if you have any questions or doubts. Please carefully read our full "Risk Disclosure" and "Risk Disclosures for Financial Instruments & Investment Services". FXFINPRO Capital is the trading name of PFX Financial Professionals Limited, a limited liability company formed under the laws of Cyprus, registered with the Registrar of Companies in Nicosia, Cyprus, under nr. HE 237840 and regulated by the Cyprus Securities and Exchange Commission with license number 193/13.